| ²é¿´: 440 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
shuxinme111½ð³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
Ò»¾ä»°·Òë¡«¡«¡«
|
|
|
To address the primary hypothesis, the mean change from baseline in A1C produced by the addition of sitagliptin treatment at Week 24 in the entire cohort will be compared to that of placebo using the least-squares (LS) means of the sitagliptin and placebo treatment groups as estimated via analysis of covariance (ANCOVA). Ö÷Òª²»ÊǺÜÀí½âºóÃæas estimated via analysis of covariance (ANCOVA). µÄÒâ˼£¬µ½µ×ÊÇÓÃLS»¹ÊÇANCOVA½øÐа¡£¿£¿£¿ÇóÖ¸µã¡«¡«¡« |
» ²ÂÄãϲ»¶
312Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
0703µ÷¼Á£¬Ò»Ö¾Ô¸Ìì½ò´óѧ319·Ö
ÒѾÓÐ9È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ10È˻ظ´
ר˶0854³õÊÔ¿¼²Ä¿Æ»ù£¬Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
085600£¬320·ÖÇóµ÷¼Á
ÒѾÓÐ17È˻ظ´
297·Ö083200ÇóÖú
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸±±½»´ó²ÄÁϹ¤³Ì×Ü·Ö358Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
liufuliang
гæ (ÖªÃû×÷¼Ò)
- ·ÒëEPI: 19
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 61.9
- É¢½ð: 1273
- ºì»¨: 4
- ɳ·¢: 1
- Ìû×Ó: 7909
- ÔÚÏß: 274.7Сʱ
- ³æºÅ: 98678
- ×¢²á: 2005-11-10
- ÐÔ±ð: GG
- רҵ: ²¡Ôϸ¾úÓë·ÅÏß¾úÉúÎïѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
Mally89: ½ð±Ò+1, ¸ÐлӦÖú£¡~»¶Ó³£À´£¡~ºðºð£¡~\(^o^)/~ 2012-03-16 22:13:34
shuxinme111: ½ð±Ò+8, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú, thank you~~~~ллÄãµÄ·ÖÎö¡«¡«¡« 2012-03-21 21:01:01
Mally89: ½ð±Ò+1, ¸ÐлӦÖú£¡~»¶Ó³£À´£¡~ºðºð£¡~\(^o^)/~ 2012-03-16 22:13:34
shuxinme111: ½ð±Ò+8, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú, thank you~~~~ллÄãµÄ·ÖÎö¡«¡«¡« 2012-03-21 21:01:01
|
using the least-squares (LS) means of the sitagliptin and placebo treatment groups as estimated via analysis of covariance (ANCOVA). ºóÃæµÄ2¸ö²¿·ÖÊDz¢Áеģ¬Ê¹Óà least-squares (LS) means of the sitagliptin ºÍ placebo treatment groups as estimated via analysis of covariance (ANCOVA). ºóÃæµÄ as estimated via analysis of covariance (ANCOVA). ÊÇÐÞÊÎplacebo treatment groups ¡£ |

2Â¥2012-03-16 16:07:25














»Ø¸´´ËÂ¥